TransMedics Group’s (TMDX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a report published on Wednesday,Benzinga reports.

A number of other research firms have also commented on TMDX. Piper Sandler lowered their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Oppenheimer restated an “outperform” rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $72.60 on Wednesday. TransMedics Group has a 12-month low of $55.00 and a 12-month high of $177.37. The company’s 50 day moving average price is $66.39 and its two-hundred day moving average price is $110.16. The firm has a market cap of $2.44 billion, a PE ratio of 77.23 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TMDX. Hager Investment Management Services LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth $33,000. Sachetta LLC bought a new position in TransMedics Group during the 4th quarter worth $40,000. AlphaQuest LLC acquired a new position in TransMedics Group during the 4th quarter worth about $52,000. USA Financial Formulas bought a new stake in shares of TransMedics Group in the 3rd quarter valued at about $55,000. Finally, Quarry LP increased its stake in shares of TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.